A 30% decline in spleen volume 12 months after 177Lu-DOTATATE treatment predicted leukopenia at 24 months with 91% accuracy, outperforming all standard blood tests.
AUC 0.91 predictionSpleen volume reduction at 12 months predicted leukopenia at 24 months with 91% accuracy (93% sensitivity, 90% specificity) — far outperforming blood count monitoring for early detection
What the researchers found
A 30% decline in spleen volume at 12 months post-177Lu-DOTATATE treatment predicted leukopenia at 24 months with AUC 0.91, sensitivity 93%, and specificity 90%. White blood cell counts and relative spleen volume reduction were also independent predictors, but spleen volume reduction was far superior. Automated splenic volume assessment outperformed all conventional laboratory parameters.
Why it matters
Leukopenia (low white blood cells) after PRRT is a serious complication that increases infection risk and may force treatment discontinuation. Currently, clinicians rely on blood tests that detect the problem only after it's developing. Spleen volume — measurable on routine CT scans already being performed for tumor monitoring — provides much earlier warning, allowing proactive management.
The numbers in context
88 patients analyzed. Spleen volume reduction was identified as a reliable, independent biomarker for leukopenia risk.
How the study worked
Retrospective analysis of 88 patients with metastatic neuroendocrine tumors treated with 177Lu-DOTATATE from February 2009 to July 2021. Inclusion: ≥4 treatment cycles, ≥24 months follow-up, tumor uptake ≥ liver on baseline receptor imaging. Blood counts and imaging data analyzed for predictive markers of radiation-induced leukopenia.
Who was studied
Patients with metastatic neuroendocrine tumors receiving 177Lu-DOTATATE
What this study cannot tell us
Retrospective single-center study with moderate sample size. Exclusion of patients with <24 months follow-up and <4 treatment cycles may introduce survival bias. The optimal timing for spleen volume assessment and the generalizability to different treatment protocols need prospective validation. Automated splenic volumetry requires appropriate software.
How to read the evidence
Moderate evidence from a well-designed retrospective cohort with strong predictive performance. Needs prospective validation in independent cohorts before clinical implementation.
When this study was published
Published in 2024, with data spanning 2009-2021, providing a long follow-up period for assessing late hematotoxicity.
The bigger picture
PRRT is expanding as a treatment option for neuroendocrine tumors, and managing hematotoxicity is crucial for patient safety. Finding an imaging-based biomarker that outperforms blood tests is particularly valuable because these CT scans are already routinely performed — no additional testing is needed, just automated measurement of an organ already visible on the scan.
Questions still open
- Could spleen volume monitoring be used to guide dose modifications during PRRT to prevent leukopenia?
- Does spleen volume reduction also predict other hematotoxicities like thrombocytopenia after PRRT?
Common questions
Why does the spleen shrink after PRRT?
What is 177Lu-DOTATATE?
Read the original research
Spleen Volume Reduction Is a Reliable and Independent Biomarker for Long-Term Risk of Leukopenia Development in Peptide Receptor Radionuclide Therapy.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 65(8), 1244-1249
Citation
Steinhelfer, Lisa; Jungmann, Friederike; Endrös, Lukas; Wenzel, Patrick; Haller, Bernhard; Nickel, Manuel; Haneder, Eva; Geisler, Fabian; Götze, Katharina; von Werder, Alexander; Eiber, Matthias; Makowski, Markus R; Braren, Rickmer; Lohöfer, Fabian. (2024). Spleen Volume Reduction Is a Reliable and Independent Biomarker for Long-Term Risk of Leukopenia Development in Peptide Receptor Radionuclide Therapy.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 65(8), 1244-1249. https://doi.org/10.2967/jnumed.123.267098